Chapter 3. Risk Factors for Progression of Chronic Kidney Disease

  1. Donald A. Molony MD4,5 and
  2. Jonathan C. Craig MD, PhD6,7
  1. Eberhard Ritz MD1,
  2. Danilo Fliser MD2 and
  3. Marcin Adamczak MD3

Published Online: 4 MAR 2009

DOI: 10.1002/9781444303391.ch3

Evidence-Based Nephrology

Evidence-Based Nephrology

How to Cite

Ritz, E., Fliser, D. and Adamczak, M. (2008) Risk Factors for Progression of Chronic Kidney Disease, in Evidence-Based Nephrology (eds D. A. Molony and J. C. Craig), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303391.ch3

Editor Information

  1. 4

    Division of Renal Disease and Hypertension, University of Texas, USA

  2. 5

    Houston Medical School, Houston, Texas, USA

  3. 6

    School of Public Health, University of Sydney, Australia

  4. 7

    Department of Nephrology, The Children's Hospital at Westmead, Sydney, Australia

Author Information

  1. 1

    Department of Internal Medicine, Division Nephrology, Ruperto Carola University, Heidelberg, Germany

  2. 2

    Department of Internal Medicine, Division of Nephrology, Medical School Hannover, Hannover, Germany

  3. 3

    Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Poland

Publication History

  1. Published Online: 4 MAR 2009
  2. Published Print: 5 DEC 2008

ISBN Information

Print ISBN: 9781405139755

Online ISBN: 9781444303391



  • chronic kidney diseases (CKD) risk factors;
  • assessment of CKD progression;
  • quantification of albuminuria and proteinuria;
  • RAAS blockade;
  • progression of nephropathy in type 2 diabetes;
  • RAAS blockade with irbesartan and their interaction;
  • US National Kidney Foundation - ARBs or ACEi as first-line antihypertensive agents for diabetic renal disease


This chapter contains sections titled:

  • Evidence for progression of primary and secondary chronic kidney diseases

  • Assessment of CKD progression

  • Prevention of progression of CKD

  • References